Eli Lilly and Company Revenue Growth: -2.27%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
LLY Revenue Growth Rankings
| Overall | 26th percentile | 3246 of 4424 |
| Sector | 26th percentile | 341 of 464 in Healthcare |
| Industry | 25th percentile | 15 of 20 in Drug Manufacturers - Major |
LLY Revenue Growth Range, Past 5 Years
| Minimum | -16.08% | Mar 1994 |
| Maximum | 84.16% | Dec 1990 |
| Average | 8.71% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these LLY related companies
LLY News
Diabetes Self-Management Magazine|FDA Approves Combo Type 2 Medicine http://stks.co/2MCG $LLY
about 2 days ago by abubnic
about 2 days ago by abubnic
FDA approves $LLY Jentadueto™tablets for the treatment of adult patients with type 2 diabetes. http://stks.co/2MCA
about 2 days ago by abubnic
about 2 days ago by abubnic
Notable Stocks Trading Ex-Dividend Monday 02/13: (STX) (LLY) (IP) (EXC) (DD)
Feb 10, 10:57AM Street Insider
Feb 10, 10:57AM Street Insider
Perception, Opportunity in Volatility - Research & Analysis on VIVUS, Inc. and Eli Lilly & Co.
Feb 09, 9:00AM Marketwire
Feb 09, 9:00AM Marketwire
Fifth Lilly Oncology on Canvas Art Competition Invites All Touched by Cancer to Share Their Cancer Journeys
Feb 09, 8:00AM PR Newswire
Feb 09, 8:00AM PR Newswire
AMAG Pharmaceuticals (AMAG) Adds Rajiv De Silva and Gino Santini to Board
Feb 07, 4:31PM Street Insider
Feb 07, 4:31PM Street Insider
Reviewing our covered $CALL trades on $COP & $LLY that expired back in January http://stks.co/2Hh0 $$
about 5 days ago by GlennBusch
about 5 days ago by GlennBusch
European Urology Study Shows Lilly (LLY) Phase III of Cialis and Tamsulosin Improves BPH
Feb 07, 8:24AM Street Insider
Feb 07, 8:24AM Street Insider
$LLY freezing pay for employees due to financial problems caused by expiration of patents http://stks.co/2F9B
about 9 days ago by sld
about 9 days ago by sld
$LLY trading above 10DMA on high advancing volume today & yesterday.
about 12 days ago by stubbybrown
about 12 days ago by stubbybrown
bill gunderson's daily stock market radio show will be live in 15 min. $PFE $NHI $LLY etc. #Howard Lindzon on next week.
about 12 days ago by billgunderson
about 12 days ago by billgunderson
RT @lamonicabuzz Pfizer, Eli Lilly beat on EPS & sales. $PFE $LLY each up 1% pre-market despite $PFE outlook cut on strong $.
about 12 days ago by StockTwits
about 12 days ago by StockTwits
This is your market on drugs. Pfizer, Eli Lilly beat on EPS & sales. $PFE $LLY each up 1% pre-market despite $PFE outlook cut on strong $.
about 12 days ago by lamonicabuzz
about 12 days ago by lamonicabuzz
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| LLY | 39.31 | -0.21 | -0.53% | 45.51B |
| APA | 105.13 | -1.55 | -1.45% | 40.36B |
| DELL | 17.75 | -0.31 | -1.72% | 32.38B |
| VCLK | 19.64 | -0.70 | -3.44% | 1.62B |
| DAL | 10.89 | -0.23 | -2.07% | 9.21B |
| AFFY | 10.47 | -0.06 | -0.57% | 372.21M |
| IBKR | 15.61 | 0.30 | 1.96% | 711.35M |
| GNW | 8.73 | -0.17 | -1.96% | 4.29B |
| AMZN | 185.54 | 0.56 | 0.30% | 84.37B |
| GOOG | 605.91 | -5.55 | -0.91% | 196.25B |
